Korsana Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $133.52M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Sep 11, 2026 | After market close | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 12, 2023 | After market close | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 22, 2023 | After market close | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 9, 2022 | After market close | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 4, 2022 | After market close | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Feb 24, 2022 | After market close | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Nov 9, 2021 | After market close | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Jul 29, 2021 | After market close | – | – | – |
| Q1 FY2021 Ended Mar 31, 2021 | Apr 27, 2021 | Before market open | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Jan 13, 2021 | Before market open | – | – | – |
| Q2 FY2020 Ended Jun 30, 2020 | Jul 9, 2020 | After market close | – | – | – |
| Q1 FY2020 Ended Mar 31, 2020 | Apr 14, 2020 | After market close | – | – | – |
Press releases
Announcements Korsana Biosciences filed with the SEC
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
thousands, except share and per share amounts)
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
KORSANA’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
in this presentation has been prepared by Korsana Biosciences, Inc. and its affiliates (“Korsana” or the “Company”) and contains information pertaining to the business and operations of the Company. The information contained
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Cyclerion Therapeutics - Korsana Biosciences
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study
Regulation FD disclosure · EX-99.1 to Form 8-K
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapies th Investor Call: January 6 , 2026
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapies Investor Call th September 24 , 2025, 10:30am EST
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Cyclerions sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Regina Graul, Ph.D., Promoted to Chief Executive Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
Cyclerion Appoints Regina Graul, Ph.D., as President
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cyclerion Strengthens Board of Directors with Experienced Company Builder
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K
Cyclerion Announces Reverse Stock Split
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
Regulation FD disclosure · EX-99 to Form 8-K
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
Other events · EX-99.1 to Form 8-K
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in
Regulation FD disclosure · EX-99.1 to Form 8-K
Clinical Data Update from Study of CY6463 in CIAS Thursday, July 28, 2022 8:00 am EDT Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
Regulation FD disclosure · EX-99.1 to Form 8-K
Thinking differently about cognition CORPORATE Presentation June 2022 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K